TIVICAY (ViiV Healthcare Pty Ltd)
Product name
TIVICAY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
166 working days (255)
Active ingredients
dolutegravir
Registration type
EOI
Indication
TIVICAY (film-coated tablet) is now indicated for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in adults and children over 6 years of age (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Dual regimens).